With the aging US population, we can expect a greater incidence of peripheral vascular disease (PVD) (both arterial and venous disease) and substantial costs associated with its treatment. 1, 2, 3 Accordingly, the Institute of Medicine has listed the comparison of various therapies for treatment of vascular claudication alone among its top 50 comparative effectiveness research topics, and vascular claudication is the only cardiovascular condition besides atrial fibrillation on this list. 4 Recent advances in therapies for PVD have provided greater options for patients and clinicians. Several mechanical devices are now available for endovascular treatment of lower extremity peripheral artery disease (PAD), 5, 6 extra-and intra-cranial cerebrovascular disease, and aortic disease. 7 For patients with advanced PAD with development of critical limb ischemia (CLI), there remains promise for treatment with novel biologic compounds. 8, 9 Furthermore, there has been an evolution in prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolus (PE) with novel anticoagulation therapies, as well as the potential for catheter-directed thrombolysis to prevent post-thrombotic syndrome and improve quality of life. 10, 11 Similarly, percutaneous ablation of lower extremity venous disease has largely replaced traditional surgical phlebectomy for treatment of venous claudication and venous reflux. 12 While the number of PVD therapies has grown rapidly, little is known about the current state of the entire PVD trial portfolio and current trial designs. Using a database developed for analysis of trials registered in ClinicalTrials.gov (CTG), we sought to describe the current state of clinical trials for treatment of PVD.
Methods

ClinicalTrials.gov
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Transformation Initiative (CTTI) is a public-private partnership developed by the US Food and Drug Administration (FDA) and Duke University, and includes more than 60 member organizations from across the clinical trial enterprise, with the mission to identify and promote practices that will increase the quality and efficiency of clinical trials. CTTI has developed a high-quality, downloadable relational database of information contained in CTG.
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Development of the CTG Data Set
A data set of 96,346 clinical trials registered in CTG was downloaded in XML format on September 27, 2010. The data were subsequently captured in a database to facilitate aggregate analysis of data from CTG as described previously.
15,16
Creation of the PVD Data Set
Analysis was restricted to 40,970 studies with the "interventional" study type registered with This yielded a final data set of 676 PVD trials.
Subgroups of PVD Data Set
Each of the PVD studies was categorized into trials of arterial disease and/or venous disease (Figure 1) , and then further subcategorized (Figure 2 ). Descriptions and rationale for these subcategories are provided in the online-only Data Supplement.
Analysis
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Lead sponsor was defined as the primary organization that oversaw implementation of the study and was responsible for data analysis (e.g., National Institutes of Health or a pharmaceutical company). Collaborators were defined as other organizations (if any) that provided support, including funding, design, implementation, data analysis, and reporting. The assumed funding source was derived using the lead sponsor and collaborators fields, and is described in the onlineonly Data Supplement. International regional variation was described by location of enrolling sites. We compared the characteristics of the PVD studies with characteristics of cardiology trials (excluding any PVD studies), as well as the entire cohort of studies in CTG. The online-only Data Supplement includes data on the methodology for identification of cardiac trials by cardiology specialists at Duke University; these data have been previously presented 17 Within n t th he h U Uni ni n te e ed d d S St Stat at ate es es, , we we we f fu ur urt ther r d de escr r rib b bed th th he e g g geo og ogra rap ph hic ic a a acc ces ess s s t to to P PVD VD VD c cli l ni ni nica ca al l t tr trial i ite te tes s s gr gr grap ap phi hi hica ca call lly y y on n n a a m map ap a by y y lo lo oca ca cati ti tin ng ng t tri ri ial al al s s sites es es a a at t t the he cou ou ount n nty y y le le l v ve vel. l l. S S Stu tu udy dy dy t si si ite te tes s s we we were re re e ex xc xclu 
Comparison of PVD Studies Versus Other Disciplines
PVD trials were much more likely to investigate the use of devices and procedures, and less likely to investigate drug, behavioral, and genetic therapies compared to studies of noncardiology disciplines. Rates of randomization were similar among PVD and other disease states (71% versus 68%, respectively). However, compared with trials of other disease states, PVD studies were more likely to be double-blinded than the aggregate of studies of other disciplines ( Table 1) . Similar to cardiology trials, PVD studies were more likely to be later phase and larger compared with studies of other disciplines. Though the use of an active comparator was greater than in non-cardiology disciplines, it was used in less than half the PVD studies (47%). Similar to other disciplines, a placebo comparator was used in roughly one-fourth of the PVD trials.
Similar to cardiology trials, few PVD studies (4%) excluded elderly participants (those aged >65 
Arterial and Venous Disease Trials
Most trials of supra-aortic, aortic, and lower extremity PAD sought to investigate device therapies for treatment: For (a) supra-aortic disease, 67% of intra-cranial studies were examining device therapies, and 67% of extra-cranial trials investigated devices; for (b) aortic disease, 62%
of thoracic and 67% of abdominal/aorto-iliac studies were investigating devices; and for (c) lower extremity PAD, 53% of intermittent claudication studies, 50% of CLI studies, and 67% of acute limb ischemia studies investigated devices (online-only Data Supplement Table 1 ).
Behavior modification was investigated in 10% of the intermittent claudication trials. For CLI, 17% of trials investigated genetic or biologic therapies. While intermittent claudication trials tended to be later phase (87% Phases 2-4), CLI trials included earlier phase therapies (33% Phase 1 or 1/2). Meanwhile, for acute stroke, most trials were examining use of drug therapies (66% of trials for ischemic stroke and 74% for hemorrhagic stroke).
Most venous disease trials were examining either treatment or prevention of DVT or PE (57% [104/183]), with 8 of these studies of treatment using vena cava filters. A large percentage
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Geographic Variation
Geographic access to PVD clinical trials within the United States is pictured in To dem em mon on o st st stra ra r te te te h how ow w g g geo o ogr gr grap ap aphi hic c c ac ac acce ce cess ss s t to o o a a a tr tr tria ial l l ca ca can n n di di iff ff ffer e e f f fro ro rom m m th th the e e ge ge eog og ogra ra raph ph phic i Additionally, behavior modification trials may be less common because of the potential difficulty getting subjects to comply with these interventions. The greater rate of device trials potentially reflects the need for regulatory approval with devices compared with behavior modifications. This also parallels current trends in use of minimally invasive therapies (compared with surgical treatment) of PAD seen nationally. 23 Additionally, as most studies are industry sponsored, it is not surprising that behavioral 24 therapies are under-investigated given the lack of a business case and sponsor for studies. Consequently, the burden to investigate efficacy of behavioral modification compared with more invasive therapies will likely be placed on governmental funding. On a similar note, studies investigating devices for treatment of venous disease (venous ulceration and DVT treatment) should include conservative therapies (such as compression and exercise) as an active comparator. Of note, behavior therapies have the potential to be underrepresented in the current data set as they are not covered by the Food and Drug Administration Amendments Act (FDAAA) of 2007 study registration mandate, though they do need to be included in a registry to satisfy ICMJE requirements. With respect to DVT trials investigating use of vena cava filters, none of the registered trials address longer term safety of these devices. Given current FDA concern regarding fracture, migration, and perforation of such devices, 25 future trials will need to have longer longitudinal follow-up.
There seems also to be discordance at the patient level with access to trials for PVD.
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Compounding this situation is the finding that the number of trials enrolling patients in the United States is decreasing despite the increasing number of trials for PVD. To ensure a broad representation of enrolled patients, future PVD trials should consider a wider geographic catchment area representative of the entire US population with the disease. Additional efforts to enroll patients at such locations may potentially help with recruitment in trials given higher prevalence of disease in these regions. Future efforts may need to target policy to define and ensure appropriate representation of US patients within trials, given that therapies may have different efficacy in different populations.
The present analysis provides several lessons regarding the current PVD trials portfolio.
Importantly, there is a limited footprint of non-industry funding sources in the PAD arena. This suggests that the majority of trials are done by industry to support registration and marketing.
Though such trials may promote science and care of patients, a much healthier balance of investigator-initiated, multicenter trials and comparative effectiveness studies is needed. Such burden in the areas.
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Such registries could be linked to administrative registries (such as the CMS Medicare data set)
to provide insight into longer term outcomes, as well as to determine which patients benefit most from interventional therapies. Additionally, trial methodologies other than traditional time-toevent analysis may be considered to provide greater assessment of efficacy and safety of PVD therapies. 26 There are several limitations to the CTG data set. Primarily, there is no obligation to register Phase 1 trials, or studies that that do not involve a drug, biologic, or device intervention.
not analyze symptomatic status of patients proposed for trials in this data set, fut utu u ure e e tr tria ia ials ls s s s sho ho hou uld consider differential treatment effect according to symptomatic status, given that PVD tends to pr res es sen en ent t t ac ac cro ro ross s a s s sp pe pectrum of disease.
Given th th he e e h h high gh gh c cos os ost t t of of of d dev ev vel el elop opm ment an n nd sub ub ubseu ue uent nt t t tri ri r al als s, p par arti ti ticu u ula arl rl rly y y am am mon on ong g de de d vi vi vice ce es an a d bi iol ol olog og ogic ic i s, s, , n n nov o ovel el app pp ppro ro oac c che hes to to t t t tr r ria ia ial l l de des si s gn gn gns s s wi wi ill ll ll b b be ne need ed eded ed ed. On On One e po po pote te tent nt tia al l so so olu lu luti ti t on on n t t to o o th th hes s se e g g gap ps ps ncludes partn tn ner er erin in ng g g ac ac acad ad adem m mia ia a w w wit it ith h h in in indu u ust st stry ry ry t t to o o de de d si si sign gn gn new ew ew r r reg eg egis is istr tr trie ies s s or or or l l lev ev ever er erag ag ge e e ex ex exis is i ti ti t ng n Also, trials performed outside the United States do not need to be registered unless they are conducted under an Investigational New Drug or Investigational Device Exemption. However, to increase transparency and improve the conduct and monitoring of research, 13 the ICMJE now mandates that trials be registered in a repository (such as CTG) before being published in all member journals. Consequently, it is likely that most trials are registered within CTG given the desire and necessity of scientists and industry sponsors to make their research known to the medical community. Additionally, we relied on data about trials that were entered by someone from the sponsor or funding agency. Therefore, we were limited by the appropriate categorization and medical knowledge of the person entering the data. The locations for site enrollment fields are required by NLM and are flagged as "may be required to comply with FDAAA." However, there is no consistent manner to monitor this, and it is possible that not all enrollment sites were entered or that sites may have been removed from the study record after enrollment was completed. Another major limitation of the PVD data set was that we included trials in early phase development only if they actually enrolled patients with established extracardiac vascular disease; those trials of early phase therapies with a potential target for treatment of PVD that are tested in normal subjects (those without PVD) were excluded in the present analysis. Additionally, our search strategy included condition terms (those focused on disease conditions) and not specific interventions. Given that our main goal was to identify trials seeking treatment of various disease states within PVD, this was a reasonable approach.
In conclusion, the present analysis demonstrates that PVD studies represent a small r ria ia als ls ls i i in n n ea earl rl rly y y ph phas ase e de de eve ve elo lopm m men en nt t t on on only ly i if f f th th the ey ey a a ac c ctu tu ua al lly ly enr nr nrol ol olle e ed d d p pa pati ti tien en ents ts s w w wit ith h h es es sta tab bl blis is ishe e ed ex extr tr ra--cardiac vascul ul lar ar ar d d dis is isea ea ease se se; ; th h hos os ose e tr tr tria ia ials ls s of f f ea ea earl rl rly y y ph ph phas as ase e e th th ther r rap ap apie ie ies s s wi wi with th th a a a p p pot ot oten en enti ti ial al a t t tar ar arge ge get t t fo fo for treatment t t later phase, more likely to investigate devices, more likely to be industry-sponsored and funded, and less likely to investigate behavioral interventions. There remains geographic variation in access to PVD trials for patients in the United States. In aggregate, the present analysis is the first step in understanding the clinical trial portfolio of PVD studies. It will serve as a basis for future discussions and policy aimed at changing the portfolio to reflect those questions of most clinical importance in the field. acute stroke trials. Studies were allowed to be in more than one subgroup if they enrolled patients categorized within different subgroups.
A study may have more than 1 arm type.
Regions are defined as at http://www.clinicaltrials.gov/ct2/search/browse?brwse=locn_cat. A st stud ud udy y y ma ma ay y y ha ha have e ve s sit i ites n more than 1 region. Information about location of sites was missing in 8% of studies. Derived from lead sponsor and collaborator fields. 
SUPPLEMENTAL MATERIAL
Supplemental Methods
Subcategories of Peripheral Vascular Disease (PVD) Data Set
Studies of primary and secondary prevention of vascular events were included if there was specific inclusion of patients with history of stroke, carotid disease, or lower extremity peripheral artery disease (PAD). Within the category of lower extremity PAD, given that critical limb ischemia (CLI) by definition includes ulceration or ischemic rest pain secondary to significant PAD, the subcategory of CLI trials included those trials that explicitly enrolled PAD patients with arterial ulceration or rest pain and investigated CLI treatment. Meanwhile, the arterial ulceration subcategory of lower extremity PAD studies included those studies that did not specifically define whether patients had flow-limiting PAD and those studies which specifically documented that patients had adequate arterial perfusion (such as therapies investigating treatment of diabetic foot ulcers). Studies enrolling patients with extra-cardiac vascular disease with the endpoints examining plaque regression, plaque stabilization, decrease in inflammatory biomarkers, improvements in endothelial function, and measurements of arterial vessel intimal medial thickness were categorized under the prevention of vascular events category. The subgroups of venous studies are described in Figure 1 . Studies were allowed to be in more than 1 subgroup if they enrolled patients categorized within different subgroups (e.g., studies enrolling patients with both arterial and venous ulceration were included in both the arterial ulceration subgroup and venous ulceration subgroup). Venous ulcers were included if they were CEAP class 5 or above. Trials of therapies for pressure ulcers were excluded if they enrolled patients with only pressure ulcers but did not include patients with arterial or venous ulcers.
Development of Cardiology Data Set
The cardiology subset was identified using the same method used to identify the PVD subset. Two Duke cardiologists reviewed a subset of the 2010 MeSH thesaurus and frequently occurring free-text condition terms for relevance to cardiovascular disease. An initial subset of 3503 studies were identified with at least 1 MeSH or condition term relevant to cardiovascular disease. The cardiologists manually reviewed individual studies and their listed conditions to identify those related to cardiovascular disease in adult patients. They included only those that enrolled adults (maximum age ≥18 years) and studied conditions related to the diagnosis, treatment, or prevention of diseases of the heart (e.g., cardiovascular diseases, disorders of heart structure or function, or cardiovascular imaging). Conditions related to venous and pulmonary embolic disease; general risk factors such as diabetes, smoking, and hypertension in patients without coexisting cardiology disease; and other non-cardiology populations or conditions were excluded. Studies enrolling healthy volunteers were reviewed, and those that specified no cardiac disease state were excluded. This left a final population of 2325 clinical studies. Those 248 studies that were also identified under the PVD data set were excluded from the cardiology data set (n=2077) for the analysis presented in this manuscript.
Derivation of Assumed Funding Source
If the lead sponsor was from private industry, or the National Institutes of Health (NIH) was neither a lead sponsor nor collaborator and at least 1 collaborator was from industry, then the study was categorized as industry-funded. If the lead sponsor was not from industry, and the NIH was either a lead sponsor or a collaborator, then the study was categorized as NIH-funded. Otherwise, if the lead sponsor and collaborator fields were non-missing, then the study was considered to be funded by other sources. 
